Valneva to lay off up to 15%, faces tough travel vaccine market
Valneva is deliberate to shrink its headcount by up to 15% because the French vaccine developer continues to search methods to lower prices. The firm—whose vaccines embody the Japanese encephalitis shot Ixiaro and the cholera vaccine Dukoral—noticed first-quarter 2026 revenue drop to 30.9 million euros ($36.2 million) from 49.2 million euros ($57.6 million) for a…
